Molecular mechanism for accelerated atherosclerosis in diabetes and its potential therapeutic intervention

S Yamagishi1, K Nakamura, M Takeuchi

  • 1Department of Internal Medicine III, Kurume University School of Medicine, Kurume, Japan. shoichi@med.kurume-u.ac.jp

International Journal of Clinical Pharmacology Research
|March 10, 2005
PubMed

Insights

Diabetes accelerates atherosclerosis, increasing vascular disease risk. This review explores molecular mechanisms and therapeutic targets like postprandial hyperglycemia and advanced glycation end products (AGEs).

Area of Science:

  • Cardiovascular Science
  • Endocrinology
  • Metabolic Disease Research

Background:

  • Diabetes significantly elevates the risk of atherosclerotic vascular disorders, including coronary, cerebrovascular, and peripheral artery disease.
  • Macrovascular complications in diabetes contribute substantially to patient disability and mortality.
  • Current evidence suggests limited cardiovascular benefits from strict blood glucose control alone in diabetic patients.

Purpose of the Study:

  • To review the molecular mechanisms underlying accelerated atherosclerosis in diabetes.
  • To discuss potential therapeutic interventions targeting diabetes-related vascular complications.
  • To specifically focus on the roles of postprandial hyperglycemia and advanced glycation end products (AGEs).

Main Methods:

  • Literature review of molecular mechanisms in diabetes-accelerated atherosclerosis.
  • Analysis of studies on therapeutic interventions for diabetic macrovascular complications.
  • Focus on research concerning postprandial hyperglycemia and AGEs in vascular disease.

Main Results:

  • Diabetes promotes atherosclerosis through various molecular pathways.
  • Postprandial hyperglycemia and AGEs are key contributors to vascular damage in diabetes.
  • Targeting these specific mechanisms may offer new therapeutic avenues.

Conclusions:

  • Accelerated atherosclerosis in diabetes is driven by specific molecular factors beyond general hyperglycemia.
  • Interventions targeting postprandial hyperglycemia and AGEs show promise for mitigating cardiovascular risk in diabetes.
  • Further research into these pathways is crucial for developing effective treatments for diabetic vascular complications.

Related Concept Videos

Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Type II Diabetes II: Pathophysiology01:24

Type II Diabetes II: Pathophysiology

PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.
Pathophysiology of Diabetes01:20

Pathophysiology of Diabetes

Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility, suggesting a...
Type II Diabetes I: Introduction01:26

Type II Diabetes I: Introduction

Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...